Application Note
For IHC: Use at a dilution of 1:250 - 1:500. Extensive washing may be necessary. This product does not require protein digestion or microwave antigen retrieval prior to staining. For IP: Use at 10μg/mg of lysate. By immunoprecipitation, this antibody reacts with only MUTANT p53protein under NON-DENATURING conditions. For WB: Use at a dilution of 1:2,000. Predicted molecular weight: 53 kDa. Optimal dilutions/concentrations should be determined by the researcher.
Calculated MW
Positive Control
HBL100 , HCT116 , 293T , A431
Form
Liquid
Buffer
1XPBS pH7, 20% Glycerol
Preservative
No Preservative
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
2 mg/ml (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
Gel-purified p53 containing p53 amino acids 14-389 (derived from the pSV53C p53 cDNA clone).
Purification
Protein G purified
From tissue culture supernatant
Conjugation
Unconjugated
RRID
AB_372646
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
Synonyms
tumor protein p53 , BCC7 , BMFS5 , LFS1 , P53 , TRP53
Cellular Localization
Cytoplasm , Nucleus , Endoplasmic reticulum , Mitochondrion matrix
Background
This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277). [provided by RefSeq, Dec 2016]
Database
Research Area